



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07K 7/08, 7/10, 7/02</b> <b>C07K 7/18, A61K 37/24, 37/42</b> <b>// C07K 7/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/20709</b> <b>(43) International Publication Date:</b> 26 November 1992 (26.11.92)
<b>(21) International Application Number:</b> PCT/SE92/00316 <b>(22) International Filing Date:</b> 14 May 1992 (14.05.92) <b>(30) Priority data:</b> 9101472-0 15 May 1991 (15.05.91) SE <b>(71) Applicant (for all designated States except US):</b> AKTIEBO- LAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> BARTFAI, Tamas [SE/ SE]; Brinken 3, S-182 74 Stocksund (SE). HÖKFELT, Tomas [SE/SE]; Skärviksvägen 27, S-182 61 Djursholm (SE). LANGE, Ulo [RU/SE]; Sveavägen 164, B-01, S- 113 46 Stockholm (SE). AHREN, Bo [SE/SE]; Merkuri- usgatan 11, S-223 57 Lund (SE). LINDSKÖG, Stefan [SE/SE]; Dag Hammarskjöldsvägen 4 F: 179, S-223 64 Lund (SE). CONSOLO, Silvana [IT/IT]; Via Eritrea, 62, I-Milan (IT). LAND, Tiit [RU/SE]; Professorsslingan 11-101, S-104 05 Stockholm (SE). WIESENFELD-HAL- LIN, Zsuzsanna [US/SE]; Observatoriegatan 14, S-113 39 Stockholm (SE).	<b>(74) Agents:</b> DANIELSSON, Sten et al.; AB Astra, Patent De- partment, S-151 85 Södertälje (SE). <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European pa- tent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European pa- tent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> GALANIN ANTAGONIST  <b>(57) Abstract</b> <p>A galanin antagonist which is a galanin receptor ligand is described. Further, new peptides Galanin(1-12)-Pro-Substance P(5-11), Galanin(1-12)-Pro-Bradykinin(2-9), Galanin(1-12)-Pro-Pro-Pro-(Leu<sup>5</sup>-Enkephalin(5-1)), Galanin(1-12)-Pro-Lys(ε-NH<sub>2</sub>)-Pro-(Leu<sup>5</sup>-Enkephalin(5-1)) and functional analogues and functional derivatives thereof which exhibit substantially the same galanin antagonistic effect as said peptides are disclosed. Use of the galanin antagonist, a pharmaceutical preparation comprising it and a method of treating a disorder in a mammal which depends on the physiological function of galanin at the galanin receptor are also included.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

GALANIN ANTAGONIST

The present invention relates to a galanin antagonist which is a galanin receptor ligand. Further, it relates to the peptides Galanin(1-12)-Pro-Substance P(5-11), Galanin(1-12)-Pro-Bradykinin(2-9), Galanin(1-12)-Pro-Pro-(Leu<sup>5</sup>-Enkephalin(5-1)), Galanin(1-12)-Pro-Lys(ε-NH-Pro-(Leu<sup>5</sup>-Enkephalin(5-1))) and functional analogues and functional derivatives thereof which exhibit substantially the same galanin antagonistic effect as said peptides. Use of the galanin antagonist, a pharmaceutical preparation comprising it and a method of treating a disorder in a mammal which depends on the physiological function of galanin at the galanin receptor are also included.

Background

Neuro-transmitters and hormones can induce their cellular effects by binding to and activating membrane bound receptors. The neuro-peptide galanin was isolated in 1983 from porcine upper intestine and was found to contain 29 amino acid residues (Tatemoto, K., et al, FEBS Lett., 164 (1983) 124-128). The sequences of galanin from two other mammals, rat and cow, have been described (Vrontakis M. E., et al, J. Biol. Chem. 262(1987) 16755-16758; Kaplan L. M. et al, Proc. Natl. Acad. Sci. U.S.A. 85(1988) 1065-1069 and Rökaeus Å. and Carlquist M., FEBS Lett. 234 (1988) 400-406). A comparison of the peptide sequence of galanin from the mammals rat, porcine and bovine reveals that the N-terminal amino acids 1-15 are identical. Thus, it is most likely that said conserved region will be found in galanin from other mammals, including man.

Galanin has a wide pattern of distribution, often correlating with multiple neuro-formula actions exerted in a variety of different systems.

Hitherto no galanin antagonists, which are galanin receptor ligands, have been reported. A galanin antagonist would be a useful tool in determining the physiological significance of galanin and to develop pharmaceutical preparations for the regulation of the physiological function of galanin at the galanin receptor.

#### Description of the invention

10

One aspect of the invention is directed to a galanin antagonist which is a galanin receptor ligand. Thus, the antagonistic effect of the galanin antagonist according to the invention is exercised at galanin receptors. In an embodiment of this aspect of the invention the antagonist is selected from the group consisting of the peptides

15

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Gln-Gln-Phe-Phe-Gly-Leu-Met-X,

20

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-X,

25

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Leu-Phe-Gly-Gly-Tyr-X,

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Lys-X

30

Pro-Leu-Phe-Gly-Gly-Tyr-H

wherein X represents -NH<sub>2</sub> or -OH (amide or free acid), and functional analogues and functional derivatives thereof.

35

In the specification and claims, it is intended that "functional analogues" of the peptides of the invention i.a. should comprise shorter or longer peptides, with or

without substitution of one or several amino acid residues for other amino acid residues, as long as such analogues exhibit substantially the same pharmacological function as the peptides of the invention, i.e. are  
5 galanin antagonists at the galanin receptor.

Further, it is intended that "functional derivatives" of the peptides according to the invention comprise any compound which exhibits substantially the same  
10 pharmacological function as the peptides of the invention, i.e. is a galanin antagonist at the galanin receptor. Specifically, such a compound could be one which is derived from one of the peptides of the invention, but wherein one or several amino acid residues  
15 are substituted for other chemical groups, i.e. organic as well as inorganic molecules or elements resulting in a "peptidomimetic".

It is believed that it is the structural conformation at  
20 the galanin receptor of a peptide according to the invention which is responsible for its pharmacological function as a galanin antagonist and for its affinity to the galanin receptor (thus being a galanin receptor ligand).

25 Thus, it is believed that the functional derivatives and the functional analogues comprised by the invention should have a similar structural conformation at the galanin receptor as the peptides of the invention. The  
30 surrounding of the galanin receptor could be mimicked by e.g. blood or physiological saline solution.

Another aspect of the invention is directed to the peptides

35 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-X,

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-X,

5 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Leu-Phe-Gly-Gly-Tyr-X,

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Lys-X  
|  
10 Pro-Leu-Phe-Gly-Gly-Tyr-H

wherein X represents -NH<sub>2</sub> or -OH (amide or free acid),  
and functional analogues and functional derivatives  
thereof which exhibit substantially the same galanin  
15 antagonistic effect as said peptides.

As mentioned above, the peptides may also be named  
Galanin-(1-12)-Pro-Substance P(5-11), Galanin(1-12)-Pro-  
-Bradykinin(2-9), Galanin(1-12)-Pro-Pro-Pro-(Leu<sup>5</sup>-  
20 Enkephalin(5-1)) and Galanin(1-12-Pro-Lys( $\epsilon$ -NH-)Pro-  
(Leu<sup>5</sup>-Enkephalin(5-1))), respectively.

In the experimental part of this specification the above  
listed peptides, in amide form (i.e. X = -NH<sub>2</sub>), have been  
25 named M15, M35, M36,A and M34,A, respectively.

Functional analogs may be peptides such as

30 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
(D-Arg)-Pro-Lys-Pro-Gln-Gln-(D-Trp)-Phe-(D-Trp)-Leu-Leu-X

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Gln-Phe-Phe-Gly-Leu-Met-X  
35

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Ala-Leu-Ala-Leu-Ala-Leu-Ala-X

**SUBSTITUTE SHEET**

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Ala-Leu-Ala-Leu-Ala-X

5 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Gly-Phe-Ser-Pro-Phe-Arg-X

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-X

10 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Ala-  
-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-X

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Tyr-Gly-Gly-Phe-Leu-X

15 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Leu-Phe-Gly-Gly-Tyr-X

20 wherein X represents -NH<sub>2</sub> or -OH (amide or free acid).

A further aspect of the invention is directed to the use  
of a galanin antagonist which is a galanin receptor  
ligand for the preparation of a pharmaceutical  
preparation. It can be mentioned that the above listed  
25 peptides are soluble in water, which facilitates the  
preparation of a pharmaceutical preparation for  
injection.

30 Yet another aspect of the invention is directed to a  
galanin antagonist which is a galanin receptor ligand for  
use in a pharmaceutical preparation.

35 Yet a further aspect of the invention is directed to a  
pharmaceutical preparation comprising a galanin  
antagonist which is a galanin receptor ligand as an  
active ingredient, together with pharmaceutically  
acceptable additive(s). Depending on the specific type of

pharmaceutical preparation to be prepared, such additive(s) should be chosen to make up the desired preparation. Suitable additive(s) for the specific type of preparation to be prepared, such as solutions for  
5 injection, tablets or plasters, can be found in the U.S. Pharmacopoeia.

Thus the present invention also provides compositions containing an effective amount of compounds of the  
10 present invention, including the nontoxic addition salts, amides and esters thereof, which may, alone, serve to provide the above-recited therapeutic benefits. Such compositions can also be provided together with  
15 physiologically tolerable liquid, gel or solid diluents, adjuvants and excipients.

These compounds and compositions can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar  
20 to other therapeutic agents. In general, the dosage required for therapeutic efficacy will range from about 0.01 to 1000 mcg/kg, more usually 0.1 to 1000 mcg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an  
25 extended period of time until the desired therapeutic benefits have been obtained.

Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms  
30 suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified or incorporated in drug delivery systems like liposomes or microspheres. The active ingredient is often mixed with diluents or excipients  
35 which are physiologically tolerable and compatible with the active ingredient. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or



the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH-buffering agents, and the like.

5

The compositions are conventionally administered parenterally, by injection, for example, either subcutaneously, intramuscularly, intraperitoneally or intravenously. Additional formulations which are suitable for other modes of administration include suppositories, 10 vagitories, intranasal aerosols, buccal formulations like adhesive tablets, gels or patches and in some cases, oral formulations. For suppositories and vagitories, traditional binders and excipients may include, for 15 example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10% preferably 1%-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of 20 mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained-release formulations, or powders, and contain 10%-95% of active 25 ingredient, preferably 25%-70%.

The peptide compounds may be formulated into the compositions as neutral or salt forms. Pharmaceutically acceptable nontoxic salts include the acid addition salts 30 (formed with the free amino groups) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may be derived from 35 inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino

**SUBSTITUTE SHEET**

ethanol, histidine, procaine, and the like.

Still another aspect of the invention is directed to a method of treating a disorder in a mammal which depends  
5 on the physiological function of galanin at the galanin receptor, which comprises administering to said mammal a pharmacologically effective amount of a galanin antagonist which is a galanin receptor ligand. Since the physiological function of galanin at the galanin receptor  
10 is specific for each individual, the pharmacologically effective amount of a galanin antagonist which is to be administered to treat a disorder in a mammal has to be decided by a physician or veterinary on an individual bases.

15 Galanin antagonists would be useful in the regulation of at least the following:  
insulin release,  
growth hormone release,  
20 acetylcholine release,  
dopamine release,  
Substance P release,  
Somatostatin release,  
Noradrenaline release.

25 At present, the presumed fields of medical indication are endocrinology, food intake, neurology and psychiatry: senile dementia of Alzheimer's type, schizophrenia, analgesia, intestinal diseases.

30 Preparation of a galanin antagonist according to the invention

35 Conventional methods of preparing peptides can be used to prepare the galanin antagonists of the invention, suitably modified if the antagonist is a peptidomimetic. In addition to liquid phase synthesis, conventional

**SUBSTITUTE SHEET**

procedures for synthesizing the novel compounds of the present invention include any solid phase peptide synthesis method. In such a method the synthesis of the novel compounds can be carried out by sequentially  
5 incorporating the desired amino acid residues one at a time into the growing peptide chain according to the general principles of solid phase methods.

Abbreviations used in the following:

10

NMP	= N-Methylpyrrolidone
HOBt	= N-hydroxybenzotriazole
MBHA	= p-Methylbenzhydramine
PAM	= p-Acetoxymethyl
15 Boc	= tert-Butyloxycarbonyl
DMSO	= Dimethylsulfoxide
DIEA	= diisopropylethylamine
Tos	= tosyl
OcHex	= cyclohexyl ester
20 4-MeBzl	= 4-methylbenzyl
OBzl	= benzyl ester
Bom	= t-Benzyloxymethyl
Clz	= 2-Chlorobenzyloxycarbonyl
Bzl	= O-benzyl
25 For	= formyl
Brz	= 2-bromobenzyloxycarbonyl
TFA	= trifluoroacetic acid
DMS	= dimethyl sulfid
DCM	= dichloromethan
30 DMF	= N,N-dimethylformamide

The peptides "M15", "M35" and "M36,A" of this invention were assembled in a step-wise manner on a solid support using an Applied Biosystems Model 431A Peptide  
35 Synthesizer using the standard NMP/HOBt Solvent-Activation strategy on a 0.1 mmole scale (small scale).

**SUBSTITUTE SHEET**

The peptide "M34,A" was synthesized in the same manner, except for the protective group which was  $\epsilon$ -Fmoc and Boc for Lys. Accordingly one part of the peptide was synthesized using Boc-chemistry, and the other part was synthesized using Fmoc chemistry.

The functional derivatives of the invention were prepared in analogous manner.

tert-Boc-amino acids were coupled to tert-Boc-amino acid-PAM (Nova Chemical Company Ltd., UK) resin for free acid (X = -OH) or MBHA (Bachem Feinchemikalien AG, Switzerland) resin for amide (X = -NH<sub>2</sub>) as hydroxybenzotriazole (HOBt) esters.

As individual cycle for each amino acid included deprotection of the tert-Boc-group with 50% trifluoroacetic acid in CH<sub>2</sub>Cl<sub>2</sub> (DCM) for 19 min, and acylation with 10-fold excess (compared to the amount of amino groups on a resin) of the protected amino acids in a mixture of 15% DMSO in N-methyl pyrrolidone (NMP) for 35 min. Between each operation several extensive washings were performed with CH<sub>2</sub>Cl<sub>2</sub>, DIEA and NMP. After each coupling acetylation (capping) was carried out using 10% acetic anhydride and 5% DIEA in NMP for 5 min.

With the exception of Boc-Lys(Fmoc) in the case of the peptide 34,A, all amino acids used were tert-Boc-protected at the N-terminal (obtained from Nova Chemical Company Ltd., UK), and their reactive side chains were protected with Tos in

Arg, OcHex in Asp, 4-MeBzl in Cys, OBzl in Glu, Bom in His, ClZ in Lys, Bzl in Ser and Thr, For in Trp, and Brz in Tyr.

All the solvents and other reagents for automatic peptide synthesis were from Applied Biosystems.

5 The reagents used in deprotection and cleavage steps were of analytical grade and used without further purification:

1,2-ethanedithiol, acetic anhydride, trifluoromethyl sulfonic acid (TFMSA), dimethyl sulfide (DMS) and p-cresol from Fluka, diethyl ether and acetonitrile from Merck and HF from AGA Gas.

15 The fully assembled peptide-resins were dried under high vacuum overnight. Deprotection from formyl-group on Trp and benzyl-groups was performed using "low TFMSA" method. For that 100 mg of peptide-resin was treated with 2 ml of the mixture of TFMSA(10%), TFA(50%), DMS(30%), p-cresol(8%) and dimercaptoethan(2%) for 2 h at 0°C while shaking, the procedure was followed by washing with EtOH, 20 DCM, DMF, DIEA/DCM, DMF and DCM.

After drying under vacuum the peptide was cleaved from resin and deprotected by mixing of 10 ml liquid HF (containing 20% of 1:1 mixture of p-cresol and p-thiocresol) with 1 g of peptide-resin at 0°C for 60 min. 25 The resin was washed 2 times with 10 ml of Et<sub>2</sub>O, peptide extracted with 20% acetonitrile/water and filtered. Lyophilization of the aqueous filtrate yielded the crude peptide.

30 Preparative purifications were carried out on the crude product by HPLC on reversed phase C18 column. 10 mg of crude peptide was dissolved in 1 ml of 20% acetonitrile/water and eluted with a gradient (45 min) of 35 20-60 % mixture of 0.1% TFA/acetonitrile in 0.1 &

**SUBSTITUTE SHEET**

TFA/water at a flow rate of 2.0 ml/min. The fractions were collected according to the absorption detected at 238 nm.

- 5 Purity of the individual peptides was checked by analytical HPLC and determined to be 99 %. Molecular weights of the peptides were determined using Plasma Desorption Mass Spectrometer (PDMS) Model Bioion 20, Applied Biosystems, the calculated molecular weight
- 10 values were obtained in each case for the purified peptide.

Table.

Purity of the individual peptides was checked by analytical HPLC and determined to be 99 %. Molecular weights of the peptides were determined using Plasma Desorption Mass Spectrometer (PDMS) Model Bioion 20, Applied Biosystems, the expected values were obtained in each case.

Galanin(1-12)-Pro-SP(5-11) amide (M15): (MW = 2199) IC<sub>50</sub> = 0.1 nM

1 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met amide  
1 5 10 12 5 7 11

Galanin(1-12)-Pro-Spantide amide (C 7): (MW = 2827) IC<sub>50</sub> = 0.2 nM

1 13 22  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-(D-Arg)-Pro-Lys-Pro-Gln-Gln-(D-Trp)-Phe-(D-Trp)-  
23 24 spantide  
-Leu-LeuNH<sub>2</sub>

Galanin(1-12)-Pro-Pro-Pro-SP(5-11) amide (M37): (MW = 2392) IC<sub>50</sub> = 40 nM

1 5 12 22  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met amide  
5 11

Galanin(1-13)-Ala-Leu-Ala-Leu-Ala-Leu-Ala amide (M 38): (MW = 1970)  
IC<sub>50</sub> = 0.2 nM

1 5 13 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Ala-Leu-Ala-Leu-Ala-Leu-Ala amide

Galanin(1-12)-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala amide (M 40): (MW = 1980)  
IC<sub>50</sub> = 13 nM

1 5 13 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Alaamide

Galanin(1-13)-Bradykinin(3-9) amide (M20): (MW = 2135) IC<sub>50</sub> = 1 nM

1 13 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg amide  
3 9

Galanin(1-13)-Bradykinin(2-9) amide (M 35): (MW = 2232) IC<sub>50</sub> = 0.2 nM

1 13 21  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg amide  
2 9

Galanin(1-13)-NPY(25-36) amide (M 32): (MW = 2961) IC<sub>50</sub> = 0.05 nM

1 13 25 25  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr  
amide 36

Galanin(1-12)-Ala-NPY(25-36) amide (M 88): (MW = 2935) IC<sub>50</sub> = 1 nM

1 13 25 25  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Ala-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr  
amide 36

Galanin(1-12)-Pro-Pro-Pro-Leu-enkephalin(1-5) amide (M 36): (MW = 2078)  
IC<sub>50</sub> = 40 nM

1 12 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Tyr-Gly-Gly-Phe-Leu amide  
1 5

14

Galanin(1-12)-Pro-Pro-Pro-Leu-enkephalin(5-1) amide (M 41): (MW = 2078)

IC<sub>50</sub> = 20 nM

1 12 20  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Pro-Pro-Leu-Phe-Gly-Gly-Tyr amide  
5 1

Galanin(1-13)-Lys amide (Pro-Leu-enkephalin(5-1)) (M34.A) (MW = 2223)

IC<sub>50</sub> = 10 nM

1 13 14  
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Lys amide  
N-terminus I  
Pro-Leu-Phe-Gly-Gly-Tyr  
5 1

---

IC<sub>50</sub> has been determined in displacement experiments in rat hypothalamus

SUBSTITUTE SHEET



PHARMACOLOGICAL EXPERIMENTS

1) Galanin inhibits glucose-induced insulin release,  
measured according to Ahrén, B., et al (Biochemical and  
Biophysical Research Communications, Vol. 140. No. 3,  
1986, 1059-1063). By using the same procedure as the  
cited Ahrén B., et al, a peptide according to the  
invention, M15, is now shown to block the galanin-  
inhibited insulin release in equimolar concentration.

Animals and preparation of cells.

Adult obese hyperglycemic mice (ob/ob) of both sexes were  
taken from a local non-inbred colony and starved  
overnight. The animals were killed by decapitation and  
the islets were isolated by collagenase isolation  
technique. A cell suspension was prepared essentially as  
described by Lehrmark, Å., in Diabetologia 10, 1974,  
431-438. Briefly, the islets were dissociated into single  
cells and small clusters by shaking in a  $\text{Ca}^{2+}$ - $\text{Mg}^{2+}$ -  
deficient medium supplemented with EGTA (Ethylene glycol-  
bis(beta-aminoethyl ether)N,N,N',N',-tetra-acetic acid,  
SIGMA). Thereafter, the cells were incubated at 37°C, pH  
7.4, overnight in 12 ml RPMI 1640 medium (Tissue culture  
medium from SIGMA, which contains L-glutamine and does  
not contain sodium bicarbonate) supplemented with 10% NU-  
serum TM (Collaborative Research Inc., Lexington, Ma,  
U.S.A.), 100 IU/ml penicillin, 60 µg/ml gentamycin and  
100 µg/ml streptomycin. To avoid attachment of the cells  
to the culture flasks during incubation, the suspension  
was shaken gently.

Media

The basal medium used was a HEPES buffer (N-[2-  
Hydroxyethyl]-piperazine-N'-[2-ethanesulfonic acid],  
SIGMA), pH 7.4, physiologically balanced in cations with

**SUBSTITUTE SHEET**

Cl<sup>-</sup> as the sole anion. In all cases the basal medium was supplemented with 1 mg/ml albumin.

Measurements of insulin release.

5

The kinetics of insulin release were studied by perfusing pancreatic beta-cells (approx.  $1 \times 10^6$ ) with 20 mM or 5 mM glucose mixed with Bio-Gel P-4 polyacrylamide beads (200-400 mesh, Bio-Rad Lab., Richmond, Ca, U.S.A.) in a 10 0.5 ml column. The flow rate was 0.5 ml/min and 1-3 min fractions were collected and analyzed for insulin radioimmunologically, using crystalline rat insulin as a reference.

15

Results.

After 60 min incubation in the presence of glucose (8.3 mM), galanin ( $10^{-7}$  M) completely abolished insulin release from

20

34±2 µU/ml to 3±1 µU/ml ( $P < 0.001$ ;  $N=32$ ). The peptide of the invention,

25

M 15, alone ( $10^{-6}$  M -  $10^{-9}$  M) dose-dependently counteracted the galanin-induced inhibition of insulin release.

30

Insulin release in the presence of glucose, galanin and M15 at  $10^{-6}$  M,  $10^{-7}$  or  $10^{-8}$  was 28±2 µU/ml ( $N=16$ ), 17±4 µU/ml ( $N=16$ ), and 10±3 µU/ml ( $N=16$ ), respectively. M15 at  $10^{-9}$  M was without effect.

35

As a result of the above experiments it can be concluded that the peptide of the invention, M15, counteracts the galanin-induced inhibition of insulin release in islets.

2) Galanin inhibits acetylcholine release, measured according to Fisone G., et al (Proc. Natl. Acad. Sci. vol 84, 1987, 7339-7343). By using substantially the same procedure as the cited Fisone G., et al, a peptide according to the invention, M15, is now shown to counteract the inhibitory effects of galanin on the scopolamine-induced release of acetylcholine in vivo.

#### Microdialysis Experiments

10

Surgery and basic methodology. Experiments were carried out with female CD-COBS (Charles River, Como, Italy) rats, weighing 200-260 g. Animals were anesthetized with equitensin (1% pentobarbital, 4% chloral hydrate). Guide cannula was implanted stereotoxically into the ventral hippocampus according to the following coordinates from the atlas of Paxinos and Watson (Paxinos G. and Watson C. (1986) The Rat Brain in Stereotoxic Coordinates, 2nd edn. Academic Press, Sydney.): 5 mm posterior to the bregma, 4.0 mm lateral to the midline, and 6.8 mm below the surface of the dura mater. A stylet was then inserted to keep the guide cannula patent until the next day. At the time the stylet was removed and replaced with a microdialysis probe (CMA 10, Carnegie Medicine AB, Stockholm, Sweden) containing a membrane having an exposed area of 3 x 0.5 mm. The microdialysis probe extended 3 mm beyond the end of the guide cannula; it was perfused at a constant rate of 2  $\mu$ l/min with Ringer's solution (NaCl, 147 mM; CaCl<sub>2</sub>, 2.2 mM and KCl, 4.0 mM), containing 10  $\mu$ M physostigmine sulfate and adjusted to pH 7.0 with NaOH. The initial 40 min perfusate was discarded. Thereafter, perfusates were collected every 20 min during a total perfusion period of 260 min. At the end of the collection period, the samples were immediately frozen on solid CO<sub>2</sub> and lyophilized. Acetylcholine (Ach) content was quantified by a specific radioenzymatic method described in detail by Consolo S.,

**SUBSTITUTE SHEET**

et al. (J. Neurochem. 48, (1987), 1459-1465.) and Wu C.F., et al (Neurobiol. Aging 9, (1988), 357-361.) and involving (a) the conversion of choline to phosphorylcholine in the presence of choline phosphokinase and ATP, (b) the enzymatic hydrolysis of acetylcholine to choline and acetic acid, (c) the reacylation of the resulting choline to [3H]acetylcholine with the addition of [3H]acetylcoenzyme-A, 99.9 GBq/mmol, and acetyl-coenzyme A:ChAT, and (d) the separation and scintillation counting of the resulting [3H]acetylcholine by extraction into tetraphenylboron-containing ketone phase by liquid-liquid ion exchange chromatography. Phosphorylation, hydrolysis and acetylation reactions were validated routinely.

15

The concentration of acetylcholine in each sample was calculated by linear regression based on the radioactivity of the standards (linear from 10 fmol-25 pmol acetylcholine) with the slope equal to 7800 net dpm/pmol. The coefficient of variation of the replicate perfusate samples or acetylcholine standards was approximately 3%.

20

In vitro recovery of acetylcholine through three dialysis tubings was determined as previously described (Wu et al., *ibid*). The average recovery was  $17.6 \pm 0.5\%$ .

25

At the termination of the release experiments, the placements of the dialysis probes were verified histologically by use of staining for Nissl substance.

30

SUBSTITUTE SHEET

Effect of galanin and M 15 on the scopolamine-induced release of ACh, measured "in vivo" from the rat ventral hippocampus

5	Saline	2.0 pmoles
	Scopolamine	13.1 pmoles
	Scopolamine	
	+	6.9 pmoles
	Galanin	
10	Scopolamine	
	+	9.4 pmoles
	M15	

-----

15 Galanin (1.56 nmoles) and M15 (3.12 nmoles) were injected i.c.v. 2 min before scopolamine (0.3 mg/kg, s.c.). ACh release was measured in the perfusate collected during the following 80 min, in four 20 min-fractions. The values are expressed as pmoles of ACh measured during the 20 min fraction corresponding to the peak of the

20 scopolamine-effect and corresponding to the second 20 min-fraction. The data are the means of experiments carried out in two rats (n=2).

As a result of the above experiments it can be concluded

25 that the peptide of the invention, M15, counteracts the galanin-induced inhibition of scopolamine-induced release of acetylcholine in hippocampus.

3) Effects of intrathecal galanin and C-fiber stimulation

30 on the flexor reflex has been described by Wiesenfeld-Hallin Z., et al (Brain Res. 486 (1989)205-213). By using substantially the same procedure as the cited reference, a peptide according to the invention, M15, is shown to have an antagonistic effect on intrathecal galanin-

35 induced facilitation of the flexor reflex. An other peptide of the invention, M35, has given similar results in preliminary experiments.

**SUBSTITUTE SHEET**

Electrophysiological study

In acute experiments, the magnitude of the polysynaptic hamstring flexor reflex in response to activation of high threshold afferents was examined in decerebrated, spinalized, unanaesthetized rats by recording the electromyogram (EMG) from the posterior biceps femoris/semitendinosus muscles. The animals were briefly anaesthetized with Brietal®, and a tracheal cannula was inserted. The rats were mounted in a stereotaxic frame, decerebrated by aspiration of the forebrain and midbrain and then ventilated. The spinal cord was exposed by laminectomy at thoracic level and sectioned at Th<sub>8-9</sub>. An i.t. catheter (PE 10) was implanted caudally to the transection with its tip on the left side of the lumbar spinal cord (L<sub>4-5</sub>). The flexor reflex was elicited by test stimuli to the sural nerve or its innervation area with single electric shocks (0.5 ms, 10 mA) of sufficient strength to activate C-fibres (Wall and Woolf, 1984). In some experiments a CS (conditioning stimulus) (1 Hz, 20 s) of the same strength as the test stimuli was administered to the sural nerve.

The flexor reflex was recorded as EMG activity via stainless steel needle electrodes inserted in the ipsilateral hamstring muscles. The number of action potentials elicited during the reflex was integrated over 2 s. The integrated reflex was recorded on a Gould chart recorder (Model 2400 S). During the experiments the heart rate and rectal temperature of the rat were monitored and maintained within normal limits. The proper location of the i.t. catheter was confirmed after each experiment by laminectomy.

Galanin (Bachem, Bubendorff, Switzerland) and Somatostatin (Ferring, Malmö, Sweden) were dissolved in 0.9% saline. All peptides were injected i.t. in a volume

**SUBSTITUTE SHEET**

of 10 ul followed by 10 ul saline to flush the catheter.

#### Data collection

- 5 A stable baseline reflex magnitude was established for at least 20 min before each i.t. injection or nerve CS. The effect of i.t. peptides or the nerve CS on the flexor reflex was expressed as percent change in reflex magnitude compared to baseline which was defined as 100%.
- 10 To test the interaction of galanin with other peptides or the sural CS, it was administered 1 5 min prior to the injection of the other peptides when the facilitatory effect of galanin had subsided or simultaneously with the sural CS.

- 15 The antagonistic effect of intrathecal (i.t.) M-15 on the i.t. galanin-induced facilitation of the flexor reflex was measured. The peak facilitatory effect of 30 pmol galanin was  $167.0 \pm 42.8\%$  over baseline reflex magnitude.
- 20 The antagonism of M-15, injected 5-10 min after galanin was calculated as the percentage reduction of the peak facilitatory effect of galanin. Data is expressed as meant S.E.M.

25	<u>Dose of M-15</u>	<u>n</u>	<u>% antagonism</u>
	30 pmol	4	$35.8 \pm 20.7$
	300 pmol	4	$79.3 \pm 8.4$
	3 nmol	3	$93.0 \pm 3.4$
-----			

- 30 The experiments were repeated using the peptide of the invention, M35, and similar results were achieved.

- 35 As a result of the above experiments it can be concluded that peptides of the invention counteract the intrathecal galanininduced facilitation of the flexor reflex in a dose-dependent manner.

4) Ligand binding studies were conducted. Displacement of  $^{125}\text{I}$ -galanin by galanin, galanin fragment (1-13), Substance P fragment (4-11), galanin fragment (1-13) + Substance P fragment (4-11) in equimolar concentrations and the peptides of the invention M15, M35 and M34,A was studied. The peptides of the invention proved to bind specifically to the galanin receptor.

Preparation of  $^{125}\text{I}$ -monoiodo-Tyr<sup>26</sup>-porcine galanin

Synthetic porcine galanin(1-29) was iodinated by chloramine-T-method to yield  $^{125}\text{I}$ -monoiodo-Tyr<sup>26</sup>-porcine galanin (specific activity 1800-2000 Ci/mmol), (as described by Land T., et al in: Methods in Neurosciences, Ed. M. Conn, 5, 1991, 225-234), and employed in ligand binding studies carried out at equilibrium.

Preparation of membrane fraction of Rin m 5F cells

The establishment and cell culture of Rin m 5F (a rat pancreatic  $\beta$ -tumor cell-line) cells have been described earlier (Gazdav A.F., et. al. Proc. Natl. Acad. Sci. USA, 77 (1980) 3519-3523). Briefly, the cells were grown in RPMI-1640 (Gibco) medium containing 10 % (v/v) fetal calf serum, 2.06 mM L-gluthamine, 100 IU/ml penicillin and 100  $\mu\text{g}/\text{ml}$  streptomycin in 10 %  $\text{CO}_2$  - 90 % air 37°C. They were passaged every 5 days. The cells were detached from the surface of the bottles using 0.25% trypsin containing 1 mM EDTA and centrifuged at 2000 x g for 5 min at 4°C. The pellet was exposed for 15 min to hypoosmotic 5mM HEPES buffer (pH 7.4). The suspension was centrifuged at 20000xg for 15 min, the resulting pellet was resuspended in bacitracin-containing (1 mg/mg) 5 mM HEPES-buffered Krebs-Ringer solution (137 mM NaCl, 2.68 mM KCl, 1.8 mM  $\text{CaCl}_2$ , 1 g/l glucose), pH 7.4, and used immediately in equilibrium binding experiments.



Displacement of  $^{125}\text{I}$ -galanin by galanin and galanin receptor ligands

Displacement experiments were carried out in a final  
 5 volume of 400  $\mu\text{l}$  of bacitracin-containing (1 mg/ml)  
 HEPES-buffered (5 mM) Krebs-Ringer solution, 0.05 % (w/v)  
 of BSA (pH 7.4) in the presence of 0.1 - 0.2 nM  $^{125}\text{I}$ -  
 galanin, the membrane preparation and the increasing  
 concentrations ( $10^{-12}$ - $10^{-6}\text{M}$ ) of unlabeled porcine galanin  
 10 or of other galanin receptor ligands. Samples were  
 incubated for 30 min at 37°C. Incubation was terminated  
 by the addition of 10 ml of ice-cold HEPES-buffered  
 Krebs-Ringer solution, followed by rapid filtration over  
 Whatman GF/C filters, precoated for 5 - 6 hours in 0.3 %  
 15 (v/v) of polyethyleneimine solution. Filters were washed  
 with 10 ml of assay solution. Radioactivity retained on  
 the filters was determined in a Packard gamma counter.  
 Specific binding was defined as that displaceable by 1  $\mu\text{M}$   
 galanin (or appropriate concentration of a displacer).

20 The  $\text{IC}_{50}$  values of the displacing ligands were calculated  
 from the computer-generated  $\text{IC}_{50}$  values as described by  
 Land, T., et. al. (ibid).

25 Fitting of the experimental data was carried out on a  
 Macintosh SE by means of a nonlinear least squares method  
 using the Macintosh program "KaleidGraph".

30 Displacement of  $^{125}\text{I}$ -galanin from membranes of Rin m 5F  
 by galanin receptor ligands

	$\text{IC}_{50}$
Galanin (1-29)	1 nM
M15	0.1 nM
35 Galanin fragment (1-13)	100 nM
Substance P fragment (4-11)	no displacement > 10 $\mu\text{M}$

	Galanin fragment (1-13)	}	
	+ Substance P fragment (4-11)		100 nM
	in equimolar concentrations		
	M35		0.1 nM
5	M34,A		10 nM

As is evident from the above experiments, the peptides of the invention are galanin receptor ligands.

- 10 The pharmacological experiments 1), 2) and 3) thus show that the peptides of the invention are galanin antagonists, and the experiment 4) shows that they are galanin receptor ligands. Thus, the galanin antagonists of the invention are galanin receptor ligands, unlike
- 15 other compounds which earlier have been shown to antagonize a specific effect of galanin in a specific tissue by virtue of interaction with a reaction step beyond the galanin receptor - which was involved in the biological action of galanin in that given cell type.
- 20 Such antagonism is not specific for galanin action, and is not exerted at galanin receptor. Neither it is applicable to several tissues where galanin acts, whereas the antagonists according to the present invention are bona fide antagonists in the pharmacological meaning and
- 25 exert their action at the receptor site on the outside of the cell by competing with the endogenous ligand.

#### Preparation of membranes from rat hypothalamus

- 30 Adult male rats (Sprague-Dawley, 180-200 g) were decapitated, the hypothalami quickly dissected and homogenized (10% mass/vol.) in 0.05 M TRIS-Cl buffer, pH 7.4. The homogenate was diluted tenfold and centrifuged at 1000 x g for 10 min. The supernatant was centrifuged
- 35 at 10 000 x g for 45 min and the pellet resuspended in 5 mM Hepes buffered Krebs-Ringer solution (137 mM NaCl, 2.68 mM KCl, 1.8 mM CaCl<sub>2</sub> 1 g/l glucose), pH 7.4 to yield

a final protein concentration of 1.0 - 1.5 mg/ml.

Ligand binding studies in rat hypothalamus

- 5 Displacement experiments were carried out in a final volume of 400  $\mu$ l of Hepes-buffered (5 mM) Krebs-Ringer solution, 0.05 % (w/v) of BSA (pH 7.4) supplemented with bacitracin (1 mg/ml) in the presence of 0.1 - 0.2 nM 125I-galanin, the membrane preparation from rat
- 10 hypothalami and increasing concentrations ( $10^{-12}$  -  $10^{-6}$  M) of unlabeled galanin or of other galanin receptor ligands. Samples were incubated for 30 min at 37°C. Incubation was terminated by the addition of 10 ml of ice-cold Hepes-buffered Krebs-Ringer solution, followed
- 15 by rapid filtration over Whatman GF/C filters, precoated for 5-6 hours in 0.3% (v/v) of polyethylencimine solution. The filters were washed with 10 ml of assay solution. Radioactivity retained on the filters was determined in a Packard gamma counter. Specific binding
- 20 was defined as that displaceable by 1  $\mu$ M galanin. Rat and porcine galanin resulted in indistinguishable displacement curves with the membranes from rat hypothalami.
- 25 The  $IC_{50}$  values of the displacing ligands were calculated by fitting of the experimental data on a Macintosh SE by means of a nonlinear least squares method using the program "KaleidaGraph".

CLAIMS

1. A galanin antagonist which is a galanin receptor ligand.

5

2. A galanin antagonist according to claim 1, wherein said antagonist is selected from the group consisting of the peptides

10 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub>

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-X,

15

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Leu-Phe-Gly-Gly-Tyr-X,

20 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Lys-X

|  
Pro-Leu-Phe-Gly-Gly-Tyr-H

25 wherein X represents -NH<sub>2</sub> or -OH (amide or free acid),  
and functional analogues and functional derivatives  
thereof.

3. A peptide selected from the group consisting of

30 H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub>,

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-X,

35

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-  
-Pro-Pro-Leu-Phe-Gly-Gly-Tyr-X,

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-  
-Pro-Lys-X

|  
Pro-Leu-Phe-Gly-Gly-Tyr-H

5

wherein X represents -NH<sub>2</sub> or -OH (amide or free acid),  
and functional analogues and functional derivatives  
thereof which exhibit substantially the same galanin  
antagonistic effect as said peptides.

10

4. A process for the preparation of a galanin antagonist  
according to claim 1, characterized by

a) sequentially incorporating in solid phase the desired  
amino acid residues one at a time into the growing  
peptide chain, or

15

b) coupling the amino acids stepwise in a solution phase  
using appropriate derivatized amino acids.

20

5. Use of a galanin antagonist which is a galanin  
receptor ligand for the preparation of a pharmaceutical  
preparation.

25

6. A galanin antagonist which is a galanin receptor  
ligand for use in a pharmaceutical preparation.

30


7. A pharmaceutical preparation comprising a galanin  
antagonist which is a galanin receptor ligand as an  
active ingredient, together with pharmaceutically  
acceptable additive(s).

35

8. A method of treating a disorder in a mammal which  
depends on the physiological function of galanin at the  
galanin receptor, which comprises administering to said  
mammal a pharmacologically effective amount of a galanin  
antagonist which is a galanin receptor ligand.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 92/00316

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 K 7/08, 7/10, 7/02, 7/18, A 61 K 37/24, 37/42/ C 07 K 7/12		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC5	A 61 K; C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>		
SE,DK,FI,NO classes as above		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
P,X	Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 10961- -10965, December 1991, Tamas Bartfai et al: "M-15: High-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord". --	1-7
P,X	Proc. Natl. Acad. Sci. USA, Vol. 89, April 1992 Zsuzsanna Wiesenfeld-Hallin et al: "Galanin-mediated control of pain: Enhanced role after nerve injury", see page 3334 - page 3337 --	1-7
P,X	Chemical Abstracts, volume 116, no. 11, 16 March 1992, (Columbus, Ohio, US), Stefan Lindskog et al: "The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion ", see page 108, abstract 99736t, & Eur. J. Pharmacol. 1992, 210( 2), 183- 188 --	1-7
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> * Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
18th August 1992	1992 -08- 21	
International Searching Authority	Signature of Authorized Officer	
<b>SWEDISH PATENT OFFICE</b>	 Elisabeth Carlborg	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	<p>Proc. Natl. Acad. Sci. USA, Vol. 86, December 1989            Gilberto Fisone et al: "N-terminal            galanin-(1-16) fragment is an agonist at the            hippocampal galanin receptor",            see page 9588 - page 9591.            --</p>	1-7
A	<p>Chemical Abstracts, volume 112, no. 1, 1 January            1990, (Columbus, Ohio, US), Kjeld Hermansen et            al: "On the nature of the galanin action on the            endocrine pancreas: studies with six galanin            fragments in the perfused dog pancreas ", see            page 77, abstract 807z, &amp; Acta Endocrinol.            1989, 121( 4), 545- 550            --</p>	1-7
A	<p>Chemical Abstracts, volume 111, no. 23, 4 December            1989, (Columbus, Ohio, US), Lagny-Pourmir I. et            al: "Structural requirements for galanin            interaction with receptors from pancreatic beta            cells and from brain tissue of the rat ", see            page 72, abstract 209268y, &amp; Peptides            (Fayetteville, N.Y.) 1989, 10( 4), 757- 761            --            -----</p>	1-7

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 92/00316**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the Swedish Patent Office EDP file on **01/07/92**  
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Number : *Unassigned* Confirmation No.: *Unassigned*  
International Application No. : PCT/EP2006/007389  
Applicant(s) : Claus FROBERG and Ralf-Christian SCHMIDT  
I.A. Filing Date : July 24, 2006  
Title : OVEREXPRESSION OF STARCH SYNTHASE IN  
PLANTS  
TC/Art Unit : *Unassigned*  
Examiner: : *Unassigned*  
Docket No. : 65084.000050  
Customer No. : **21967**

**MAIL STOP PCT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit herewith a copy of the references listed on the attached Form PTO-SB/08B (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Several of the references included in this Information Disclosure Statement were cited in the International Search Report (PCT/ISA/210) and Written Opinion of the International Searching Authority (PCT/ISA/237), mailed November 17, 2006, and in the International Preliminary Report on Patentability (PCT/IPEA/409), mailed September 3, 2007, for International Patent Application PCT/EP2006/007389, a copy of each of which is enclosed. Also enclosed is Applicant's Reply to the Written Opinion filed May 21, 2007.

This Information Disclosure Statement is not to be construed as a representation that a search has, or has not, been conducted. The filing of this Information Disclosure Statement is not to be construed as admission that the information cited in the Information Disclosure Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08B with the Examiner's initials in the left column in accordance with MPEP § 609 are respectfully requested.

**CONCLUSION**

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being submitted within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d). Accordingly, it is respectfully submitted that no fee is required for consideration of this Information Disclosure Statement. In the event that any fees are deemed necessary, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: January 17, 2008

By: \_\_\_\_\_

Robert M. Schulman  
Registration No. 31,196

Christopher J. Nichols, Ph.D.  
Registration No. 55,984

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, D.C. 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

RMS/CJN:cdh